Coronaviridae infectious disease
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Virus diseases caused by coronaviridae.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Coronaviridae infectious disease
- Alternative names
- Coronaviridae infectious disease
- Therapeutic area
- Infectious Disease
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Unknown
- MONDO ID
- MONDO:0005718
- Parent condition
- MONDO:0005876
Related records
Broader conditions (8)
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Nidovirales infectious disease
- Primary viral infectious disease
- Viral infectious disease
Narrower conditions (4)
- COVID-19
- Middle East respiratory syndrome
- Orthocoronavirinae infectious disease
- Severe acute respiratory syndrome
Trials (27)
- A Study to Explore the Role of Gut Flora in COVID-19 Infection
- A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
- A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
- A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
- A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
- ACTIV-2: A Study for Outpatients With COVID-19
- ACTIV-3: Therapeutics for Inpatients With COVID-19
- ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
- Assessment of Long-term Sequelae of Coronavirus Disease 2019 (COVID-19) Pneumonia With Chest CT and Pulmonary Function Tests
- Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
- AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
- BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
- Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19
- EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19
- Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
- Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19
- LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
- MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
- Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
- PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)